Roche AG\u2019s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from the Lidera study testing selective estrogen receptor degrader and complete estrogen receptor antagonist (CERAN) as an adjuvant endocrine treatment for people with ER-positive, HER2-negative, early stage breast cancer (BC).<\/p>\n
BioWorld<\/a> Clinical<\/a> Cancer<\/a> Small molecule<\/a> U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche AG\u2019s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor…\n","protected":false},"author":2,"featured_media":10465,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[8086,207,2112,8094,8092,8093,8087,3517,8089,8090,8091,134,4178,8088,3518,8095,2278],"class_list":["post-10464","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-bioworld","tag-breast-cancer","tag-cancer","tag-ceran","tag-clinical","tag-complete-estrogen-receptor-antagonist","tag-genentech-inc","tag-giredestrant","tag-olema-pharmaceuticals-inc","tag-palazestrant","tag-ribociclib","tag-roche","tag-roche-ag","tag-selective-estrogen-receptor-degraders","tag-serd","tag-small-molecule","tag-u-s"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/10464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=10464"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/10464\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/10465"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=10464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=10464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=10464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}